A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Boehringer Ingelheim

Status and phase: Terminated; Phase 1

Conditions: Macular Degeneration

Treatments: Drug: BI 754132

Study type: Interventional

Funder types: Industry

Identifiers

NCT04002310

2018-004125-92 (EudraCT Number)

1418-0001

Details and patient eligibility

About

This is a study in adults with geographic atrophy, an advanced form of age-related macular degeneration. The purpose of this study is to find out how well different doses of BI 754132 are tolerated.

The participants are in the study for about 4 months. During this time, they visit the study site about 10 times. Participants receive 1 injection of BI 754132 directly into one of the eyes affected by geographic atrophy. In this study, BI 754132 is given to humans for the first time.

The doctors compare how well participants tolerate the different doses of BI 754132. The doctors also regularly check the general health of the participants.

Enrollment: 18 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria:

• Men and women with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD): For the SRD part, the GA lesion in the study eye must be ≥ 1.9 mm2 disc area in size (approximately ≥ 0.75 disc area in size); For the MD part the total GA lesion size in the study eye must be ≥ 7.5 mm2 (approximately ≥ 3 disc area in size)

• Fellow eye is not required to have GA

• Best Corrected Visual Acuity (BCVA):

  • SRD part: BCVA of 20/100 to 20/400 Snellen (corresponding to 19 to 53 letters in the ETDRS chart) in the study eye equivalent measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol
  • MD part: BCVA score of ≤53 letters (Snellen equivalent of 20/100) in the study eye

• Age ≥ than 50 years

• Best-corrected VA in the non-study eye must have a better best-corrected VA compared to the study-eye

• Women of childbearing potential (WOCBP) cannot be included. Men able to father a child must be ready and able to use highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.

• Signed informed consent consistent with International Council on Harmonisation Good Clinical Practice (ICH GCP) guidelines and local legislation prior to participation in the trial, which includes medication washout and restrictions

• Not under any administrative or legal supervision or under institutionalization due to regulatory or juridical order

Exclusion criteria

• GA in either eye because of causes other than AMD

• History of choroidal neovascularization (CNV) in the study eye and in the fellow eye

• Previous treatment in the study eye for GA secondary to AMD within 6 months prior to screening visit (ongoing therapy with vitamin and mineral supplements is allowed)

• Additional eye disease in the study eye that could compromise

  • best corrected VA (BCVA) with visual field loss,
  • uncontrolled glaucoma intraocular pressure (IOP>24),
  • clinically significant diabetic maculopathy,
  • history of ischemic optic neuropathy or retinal vascular occlusion,
  • symptomatic vitreomacular traction,
  • genetic disorders such as retinitis pigmentosa);
  • history of high myopia > 8 diopters in the study eye and
  • anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation with Spectral Domain Optical Coherence Tomography (SD-OCT)

• Any prior intraocular surgery in the study eye other then uneventful lens replacement for cataract within 3 months prior to screening

• Aphakia or total absence of the posterior capsule. Yttrium aluminum garnet (YAG) laser capsulotomy permitted, more than 3 month prior to enrollment in the study eye

• Current or planned use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol)

• Significant disease or other medical conditions (as determined by medical history, examination and clinical investigations at screening) that may, in the opinion of the investigator result in the any of the following:

  • Put the patient at risk because of participation in the study
  • Influence the results of the study,
  • Cause concern regarding the patient's ability to participate in the study, e.g. cardiac (including tachycardia), gastro-intestinal, hepatic, renal, metabolic, dermatologic, neurological, haematological, oncological and psychiatric.

• Patients with malignancy for which the patient has undergone resection, radiation or chemotherapy within past 5 years. Patients with treated basal cell carcinoma or fully cured squamous cell carcinoma are allowed.

• Known hypersensitivity to any of the ingredients used in the Investigational Medical Product (IMP) formulation, or any of the medications used

• Active intraocular inflammation in the study eye

• Active infectious conjunctivitis in either eye

• Further exclusion criteria apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

18 participants in 5 patient groups

0.3 mg BI 754132 - SRD part

Experimental group

Description:

0.3 milligram (mg) BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. Single rising dose (SRD) part.

Treatment:

Drug: BI 754132

1 mg BI 754132 - SRD part

Experimental group

Description:

1 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part.

Treatment:

Drug: BI 754132

3 mg BI 754132 - SRD part

Experimental group

Description:

3 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part.

Treatment:

Drug: BI 754132

6 mg BI 754132 - SRD part

Experimental group

Description:

6 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part.

Treatment:

Drug: BI 754132

6 mg BI 754132 - MD part

Experimental group

Description:

6 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as 3 injections, each separated by 4 weeks (that is, Day 1, Day 29 and Day 57). Multiple dose.

Treatment:

Drug: BI 754132